Evaluating the bioequivalence of levetiracetam brand and generic oral tablets available in the Saudi market in vivo
Background: Epilepsy is a common global neurological disorder. About 30% of epileptic patients are managed with anti-epileptic Drugs (AEDs). Since 2000, Levetiracetam (LEV) has been marketed around the world as an AED under the brand name Keppra, and recently more generics are found in the Saudi mar...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Saudi Pharmaceutical Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016423002530 |